NASDAQ: KRON - Kronos Bio, Inc.

Yield per half year: -7.78%
Sector: Healthcare

Share chart Kronos Bio, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About

Kronos Bio, Inc., биофармацевтическая компания, работающая на клинической стадии, занимается открытием и разработкой новых лекарственных средств для лечения рака. Механизм продукта компании фокусируется на дисрегулируемых факторах транскрипции и сетях регуляции транскрипции, которые управляют онкогенной активностью. Его ведущим кандидатом в продукт является энтосплетиниб, селективный ингибитор тирозинкиназы селезенки у пациентов с острым миелоидным лейкозом.

More details
Компания также разрабатывает KB-0742, пероральный биодоступный ингибитор циклинзависимой киназы 9 для лечения солидных опухолей, усиленных MYC. Kronos Bio, Inc. основана в 2017 году, ее штаб-квартира находится в Сан-Матео, Калифорния.

Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

EV/EBITDA 1.95
EBITDA -0.0165
Цена ао 0.9499
Сайт http://kronosbio.com
P/BV 3.47
Число акций ао 0.05774 млрд
ISIN US50107A1043
P/S 28.06
Выручка 0.0031
Валюта usd
IPO date 2020-10-09
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Change price per day: -0.0105% (0.95)
Change price per week: +1.06% (0.9399)
Change price per month: -0.0105% (0.95)
Change price per 3 month: -32.39% (1.405)
Change price per half year: -7.78% (1.03)
Change price per year: +5.29% (0.9022)
Change price per 3 year: -94.15% (16.24)
Change price per year to date: -23.4% (1.24)
All parameters

Underestimation

Title Value Grade
P/S 11.66 1
P/BV 0.461 10
P/E 0 0
EV/EBITDA -0.327 0
Total: 5.13

Efficiency

Title Value Grade
ROA, % -52.83 0
ROE, % -70.83 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.248 10
Total: 9.2

Growth impulse

Title Value Grade
Yield Revenue, % 103.89 10
Yield Ebitda, % 590.99 10
Yield EPS, % 242.32 10
Total: 10
More

Transaction date Date of disclosure Insider Type Price Volume Quantity Share before, % Share after, % Document
28.06.2024 01.07.2024 BISCHOFBERGER NORBERT W
PRESIDENT & CEO		 Purchase 1.25 255 838 204670 0 0.36 link
27.06.2024 01.07.2024 BISCHOFBERGER NORBERT W
PRESIDENT & CEO		 Purchase 1.17 480 692 410848 0 0.73 link
12.06.2024 12.06.2024 BISCHOFBERGER NORBERT W
PRESIDENT & CEO		 Purchase 1.24 1 093 570 881913 0 1.57 link
11.06.2024 12.06.2024 BISCHOFBERGER NORBERT W
PRESIDENT & CEO		 Purchase 1.09 811 296 744308 0 1.32 link
10.06.2024 12.06.2024 BISCHOFBERGER NORBERT W
PRESIDENT & CEO		 Purchase 0.88 1 213 430 1378901 0 2.45 link
21.02.2024 23.02.2024 Frisbee Allison
SR VP, CORP OPERATIONS & LEGAL		 Sale 1.05 12 710 12105 0 -0.02 link
21.02.2024 23.02.2024 Lin Charles Y
SR VP, RESEARCH & DEVELOPMENT		 Sale 1.05 12 638 12036 0 -0.02 link
21.02.2024 23.02.2024 Olek Elizabeth A
SR VP, CLINICAL SCIENCE		 Sale 1.05 7 736 7368 0 -0.01 link
04.01.2024 05.01.2024 Kosacz Barbara
COO & General Counsel		 Sale 1.18 12 598 10676 0 -0.02 link
04.01.2024 05.01.2024 DiMartino Jorge
Chief Medical Officer & VP		 Sale 1.18 14 171 12009 0 -0.02 link
04.01.2024 05.01.2024 Dinsmore Christopher
Chief Scientific Officer		 Sale 1.18 8 692 7366 0 -0.01 link
06.12.2021 08.12.2021 BISCHOFBERGER NORBERT W
President & CEO		 Purchase 12.09 173 564 14356 0 0.03 link
20.08.2021 24.08.2021 De Backer Marianne
Director		 Purchase 19.57 19 570 1000 0 0 link

Institutions Volume Share, %
Omega Fund Management, Llc 3818283 6.35
BVF Inc. 2905043 4.83
Vida Ventures Advisors, LLC 2765314 4.6
Perceptive Advisors LLC 1752745 2.92
Vanguard Group Inc 1700677 2.83
PARTNERS CAPITAL INVESTMENT GROUP, LLP 1665797 2.77
Alphabet Inc. 1438232 2.39
Wildcat Capital Management, LLC 1297959 2.16
Blackrock Inc. 1068504 1.78
Renaissance Technologies, LLC 912926 1.52

ETF Share, % Profitability for 1 year, % Dividends, %
iShares Micro-Cap ETF 0.01246 43.316995205115 1.54048



Head Job title Payment Year of birth
Mr. Joshua A. Kazam Co-Founder & Director 40k 1977 (47 years)
Dr. Norbert W. Bischofberger Ph.D. President, CEO & Director 809.7k 1956 (68 years)
Dr. Elizabeth A. Olek D.O., M.P.H. Senior Vice President of Clinical Development N/A 1965 (59 years)
Ms. Allison Frisbee J.D. Senior Vice President of Corporate Operations & Legal N/A 1983 (41 year)
Mr. Wes Trotter Ph.D. Senior Vice President of Drug Discovery & Pharmaceutical Development N/A
Dr. Margaux Bennett Ph.D. Vice President of Corporate Development & Investor Relations N/A
Dr. Charles Lin Ph.D. Senior Vice President of Research & Development N/A 1985 (39 years)
Mr. David M. Tanen J.D. Secretary & Director 1971 (53 years)
Dr. Deborah A. Knobelman Ph.D. COO & CFO 1974 (50 years)

Address: United States, San Mateo, CA , 1300 South El Camino Real - open in Google maps, open in Yandex maps
Website: http://kronosbio.com